Oslo, Norway, October 8, 2024 - EXACT Therapeutics AS (Euronext Growth: EXTX), a
clinical stage precision medicine company utilizing the power of ultrasound to
enable targeted drug delivery in oncology, today announced a preclinical
research collaboration with Agenus Inc. (NASDAQ: AGEN) to explore the
combination of Agenus' proprietary immune checkpoint inhibitors in combination
with EXACT's Acoustic Cluster Technology, ACT®, in pancreatic cancer models.

The project substantiates EXACT's work in cancer-immunotherapy, which is the
leading type of cancer treatment, and which helps your immune system fight
cancer. Further, it is an extension of the company's announcement on September
25, 2024 of the grant of EXACT's first immunotherapy patent.

Commenting on the announcement, Per Walday, CEO of EXACT Therapeutics, said: "We
are excited to initiate a preclinical collaboration with Agenus Inc., a
late-stage oncology-focused biotechnology company. The collaboration is a
recognition of the promising results EXACT Therapeutics has demonstrated in its
preclinical work in pancreatic tumor models and in the Phase 1 ACTIVATE trial in
patients with liver metastases of colorectal origin."


For further information, please contact:

Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

About Agenus:

Agenus is a leading immuno-oncology company targeting cancer with a
comprehensive pipeline of immunological agents. The company was founded in 1994
with a mission is to expand patient populations benefiting from cancer
immunotherapy through combination approaches, using a broad repertoire of
antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and
adjuvants (through SaponiQx). Agenus has robust end-to-end development
capabilities, across commercial and clinical cGMP manufacturing facilities,
research and discovery, and a global clinical operations footprint. Agenus is
headquartered in Lexington, MA. For more information, visit www.agenusbio.com or
@agenus_bio. Information that may be important to investors will be routinely
posted on our website and social media channels.

About EXACT Therapeutics:

EXACT is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com


About ACT®:

o ACT is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.

o ACT is being tested in the clinic and has released positive interim data. It
is supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as blood-brain barrier penetration.

o Initial focus of the company is oncology. The ACT platform has potential
across many therapeutic areas (including CNS, immunotherapy) and product
classes.

Forward looking statements:

This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.